26-Jun-2006 - Greenovation Biotech GmbH

Bayer Innovation announces licensing agreement with greenovation Biotech

Bayer Innovation GmbH and greenovation Biotech GmbH have concluded a licensing and service agreement in the field of protein glycosylation in plants. This was announced by the companies today. The terms of the agreement will not be disclosed.

In this context, glycosylation is a process by which certain sugar molecules are added to proteins in plants. Understanding and controlling this process in plants can enable researchers to enhance considerably the activity or bioavailability of new proteins produced by plants which can be used for therapeutic purposes.

"Collaboration with greenovation will give us access to innovative glycosylation technology. This will complement our own skills and technologies and has particular applicability to our work on plant-made pharmaceuticals," explained Gerd Seidl, Global Project Leader for this field at Bayer Innovation GmbH.

Facts, background information, dossiers
More about Greenovation Biotech
More about Bayer
  • News

    Bayer delivers robust performance despite pandemic

    The Bayer Group delivered robust operational performance in 2020. “Our operational strength in these turbulent times shows just how resilient our businesses are, even during the pandemic,” said Werner Baumann, Chairman of the Board of Management, on Thursday during the company’s Financial N ... more

    Overcome food allergies and sensitivities

    Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, announced USD 40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding will allo ... more

    Bayer: Challenging third quarter

    Bayer has confirmed its targets for full-year 2020 following a challenging third quarter due to seasonal factors. “Despite the weak quarter and the substantial impact of the pandemic, our currency- and portfolio-adjusted sales and core earnings per share in the first nine months of the year ... more

  • Companies

    Bayer Hispania, S.L.


    Química Farmacéutica Bayer, S.L.


    Bayer Sp. z o.o.

    Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more

  • Associations

    Bayer USA Foundation

    Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more